AIDS-related Kaposi's Sarcoma in a Patient with a Normal CD4 Count

Clinical Oncology

Volumn 20, Issue 1, 2008, Pages 97-

  Power, D G ^a   Mulholland, P J ^a   O'Byrne, K J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CISPLATIN; DAUNORUBICIN; ETOPOSIDE; LAMIVUDINE; NELFINAVIR; PACLITAXEL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG TOLERABILITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; LETTER; LUNG SARCOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HUMANS; MALE; SARCOMA, KAPOSI;

EID: 38149046544     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.09.004     Document Type: Letter

References (4)

1. Portsmouth S., Stebbing J., Gill J., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. Aids 17 (2003) F17-F22
2. Bernstein W.B., Little R.F., Wilson W.H., and Yarchoan R. Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol 84 (2006) 3-11
3. Grabar S., Abraham B., Mahamat A., Del Giudice P., Rosenthal E., and Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 24 (2006) 3408-3414
4. Martinez V., Caumes E., Gambotti L., et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 94 (2006) 1000-1006